Literature DB >> 21226626

Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.

Ana Revilla1, Elena Delgado, Elizabeth C Christian, Justin Dalrymple, Yolanda Vega, Cristina Carrera, María González-Galeano, Antonio Ocampo, Rafael Ojea de Castro, María J Lezaún, Raúl Rodríguez, Ana Mariño, Patricia Ordóñez, Gustavo Cilla, Ramón Cisterna, Juan M Santamaría, Santiago Prieto, Aza Rakhmanova, Anna Vinogradova, Maritza Ríos, Lucía Pérez-Álvarez, Rafael Nájera, David C Montefiori, Michael S Seaman, Michael M Thomson.   

Abstract

Subtype G has been estimated to represent the fourth most prevalent clade in the HIV-1 pandemic and subtype F is widely circulating in parts of South America (frequently within BF recombinant forms) and in Romania. However, functional envelope clones of these subtypes are lacking, which are needed for studies on antibody-mediated neutralization, coreceptor usage, and efficiency of viral entry inhibitor drugs. Here we report the construction, neutralization properties, and coreceptor usage of HIV-1 functional envelope clones of subtypes G (n = 15) and F (n = 7). These clones were obtained through RT-PCR amplification of HIV-1 gp160 from plasma RNA, and were used for pseudovirus production. All 15 subtype G-enveloped pseudoviruses were resistant to neutralization by gp120-targeted broadly neutralizing monoclonal antibodies (MAbs) b12 and 2G12, while a majority were neutralized by gp41-targeted MAbs 2F5 and 4E10. With regard to the subtype F envelopes, all seven pseudoviruses were resistant to 2F5 and b12, six were resistant to G12, and six were neutralized by 4E10. Coreceptor usage testing revealed that 21 of 22 envelopes were CCR5-tropic, including all 15 subtype G envelopes, seven of which were from patients with CD4(+) T cell counts <200/ml. These results confirm the broadly neutralizing activity of 4E10 on envelope clones across all tested group M clades, including subtypes G and F, reveal the resistance of most subtype F-enveloped pseudoviruses to broadly neutralizing MAbs b12, 2G12, and 2F5, and suggest that, similarly to subtype C, CXCR4 tropism is uncommon in subtype G, even at advanced stages of infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21226626     DOI: 10.1089/AID.2010.0177

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  Short communication: Molecular epidemiology, phylogeny, and phylodynamics of CRF63_02A1, a recently originated HIV-1 circulating recombinant form spreading in Siberia.

Authors:  Nadezhda S Shcherbakova; Lyudmila A Shalamova; Elena Delgado; Aurora Fernández-García; Yolanda Vega; Larissa I Karpenko; Alexander A Ilyichev; Yuri V Sokolov; Dmitry N Shcherbakov; Lucía Pérez-Álvarez; Michael M Thomson
Journal:  AIDS Res Hum Retroviruses       Date:  2014-08-14       Impact factor: 2.205

2.  Construction and Characterization of HIV-1 env-Pseudoviruses of the Recombinant Form CRF63_02A and Subtype A6.

Authors:  N B Rudometova; N S Shcherbakova; D N Shcherbakov; O S Taranov; B N Zaitsev; L I Karpenko
Journal:  Bull Exp Biol Med       Date:  2022-05-02       Impact factor: 0.804

3.  Identification of Emerging Macrophage-Tropic HIV-1 R5 Variants in Brain Tissue of AIDS Patients without Severe Neurological Complications.

Authors:  Maria Paz Gonzalez-Perez; Paul J Peters; Olivia O'Connell; Nilsa Silva; Carole Harbison; Sheila Cummings Macri; Saravanan Kaliyaperumal; Katherine Luzuriaga; Paul R Clapham
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

4.  Independent evolution of macrophage-tropism and increased charge between HIV-1 R5 envelopes present in brain and immune tissue.

Authors:  Maria Paz Gonzalez-Perez; Olivia O'Connell; Rongheng Lin; W Matthew Sullivan; Jeanne Bell; Peter Simmonds; Paul R Clapham
Journal:  Retrovirology       Date:  2012-03-15       Impact factor: 4.602

5.  HIV-1 Envelope Glycoprotein Amino Acids Signatures Associated with Clade B Transmitted/Founder and Recent Viruses.

Authors:  Alexis Kafando; Christine Martineau; Mohamed El-Far; Eric Fournier; Florence Doualla-Bell; Bouchra Serhir; Adama Kazienga; Mohamed Ndongo Sangaré; Mohamed Sylla; Annie Chamberland; Hugues Charest; Cécile L Tremblay
Journal:  Viruses       Date:  2019-11-01       Impact factor: 5.048

6.  Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.

Authors:  Tumelo Moshoette; Stuart Alvaro Ali; Maria Antonia Papathanasopoulos; Mark Andrew Killick
Journal:  Retrovirology       Date:  2019-11-08       Impact factor: 4.602

7.  Anti-HIV Activity of Snake Venom Phospholipase A2s: Updates for New Enzymes and Different Virus Strains.

Authors:  Andrei Siniavin; Svetlana Grinkina; Alexey Osipov; Vladislav Starkov; Victor Tsetlin; Yuri Utkin
Journal:  Int J Mol Sci       Date:  2022-01-30       Impact factor: 5.923

8.  HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6.

Authors:  Tumelo Moshoette; Maria Antonia Papathanasopoulos; Mark Andrew Killick
Journal:  Virol J       Date:  2022-09-07       Impact factor: 5.913

9.  A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.

Authors:  Adonis A Rubio; Maria V Filsinger Interrante; Benjamin N Bell; Clayton L Brown; Theodora U J Bruun; Celia C LaBranche; David C Montefiori; Peter S Kim
Journal:  J Virol       Date:  2021-07-12       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.